Welcome and thanks for reading!
In this review, I will make a summary of important and interesting news and events over the last week related to my portfolio holdings. Also, I will put together some interesting articles from other websites that caught my attention during the past week.
Received Dividends:
October 6, 2025
- €93.49 - Canadian Natural Resources Limited (CNQ)
October 7, 2025
- €44.24 – JPM Global Equity Premium Income Active UCITS ETF (JGPI.DE)
- €14.70 – JPM US Equity Premium Income Active UCITS ETF (JEIP.DE)
- €39.84 – JPM Nasdaq Equity Premium Income Active UCITS ETF (JEQP.DE)
October 9, 2025
- €24.26 - Best Buy Co., Inc. (BBY)
October 10, 2025
- €22.93 - Global X SuperDividend™ ETF (SDIV)
Week 41: Total net dividends €239.46
Dividend income is reported after the deduction of taxes. Check more at my Monthly Dividend sheet.
My Portfolio's Transactions:
October 6, 2025
- I purchased 51 shares of JPM Nasdaq Equity Premium Income Active UCITS ETF (JEQP.DE) at €22.325 per share plus commission.
Based on the latest announcement, JEQP will pay a dividend of $0.1755 per share for October. Over the past 11th months, JEQP has declared a total dividend of $2.2206 per share. If the current level continues, this would imply an annualized dividend of $2.4225 per share.
At today’s exchange rate, my purchase of 51 shares of JEQP will increase my expected annual net dividend income by €74.14. Following this acquisition, my yield on cost stands at 10.93%, with JEQP now representing approximately 1.26% of my portfolio and accounting for about 2.65% of my future annual dividend income.
For the time being, my strategy is to continue building my JEQP position gradually through monthly purchases.
Portfolio Holdings News:
October 6, 2025
- Amgen Inc. (AMGN) makes Repatha available through ‘AmgenNow’ direct to patient program; AMGN announced that it has launched its cholesterol medication, Repatha, directly to consumers in the U.S. at a reduced cash price. In support of the Trump Administration's efforts to lower drug prices for Americans, Repatha will be available through AmgenNow at a monthly price of $239, nearly 60% lower than the current U.S. list price.
- Pembina Pipeline Corporation (TSE:PPL) Provides Update on Greenlight Electricity Centre; PPL and its partner Kineticor said Monday they are making progress on the proposed Greenlight Electricity Centre, a multi-phased gas-fired combined cycle power generation facility in Alberta, with a capacity of as much as 1,800 MW.
October 7, 2025
- NCC AB (NCC) initiates preparatory groundwork for LKAB in Gällivare, Sweden; NCC has been commissioned by LKAB to begin preparatory groundwork ahead of the construction of a new sorting plant at LKAB’s facility in Vitåfors, Gällivare. The order value amounts to approximately SEK 200 million.
October 8, 2025
- NCC AB (NCC) to construct new hospital building in Oulu, Finland; NCC has been commissioned by the Northern Ostrobothnia Hospital District to construct Building C at the Oulu University Hospital in Finland. The order value is just over SEK 1.7 billion.
- NCC AB (NCC) to build new parking facility in southern Stockholm; NCC has been commissioned to construct a new parking facility for Stockholm Stads Parkerings AB in the Slakthusområdet area, southern Stockholm. The project, Sandhagsgatan P-hus, will be carried out as a turnkey contract in collaboration and has an order value of approximately SEK 200 million.
- Verizon Communications Inc. (VZ) accelerates fixed wireless broadband expansion with acquisition of Starry; VZ announced a definitive agreement to acquire Starry, a leading provider of next-generation fixed wireless broadband services. This strategic acquisition advances Verizon's differentiated ability to deliver high-speed internet to multi-dwelling units (MDUs) and urban communities, leveraging Starry’s innovative millimeter wave technology. The acquisition is expected to close by the first quarter of 2026.
October 9, 2025
- PepsiCo, Inc. (PEP) Reports Third-Quarter 2025 Results; PEP reported second-quarter Non-GAAP EPS of $2.29, a 2.0% decline compared to the same period last year, but $0.03 above analyst expectations. Revenue grew by 2.7% year-over-year to $23.94 billion, beating estimates by $90 million. For full-year 2025, management maintains its outlook, expecting a low-single-digit increase in organic revenue and core constant currency EPS to remain roughly flat compared to the prior year.
October 10, 2025
- Bristol-Myers Squibb Company (BMY) Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics; BMY has agreed to acquire privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash. Orbital Therapeutics is advancing a new generation of RNA medicines designed to reprogram cells in vivo, treating diseases at their source. Its lead RNA immunotherapy preclinical candidate, OTX-201, targets autoimmune disease through B cell depletion to reset the immune system.
- Lockheed Martin Corporation (LMT) Announces Dividend Increase; LMT board of directors has authorized a fourth quarter 2025 dividend of $3.45 per share. This is an increase of $0.15, or 5%, per share over the last quarter and represents the company's 23rd consecutive year of dividend increases. The dividend is payable on Dec. 30, 2025, to holders of record as of the close of business on Dec. 1, 2025. LMT's board has also authorized the purchase of up to an additional $2 billion of Lockheed Martin common stock under its share repurchase program. With this increase, total authorization for future repurchases under the share repurchase program is approximately $9.1 billion.
- T. Rowe Price Group, Inc. (TROW) Reports Preliminary Month-End Assets Under Management For September 2025; TROW announced preliminary September month-end assets under management of $1.77 trillion. Preliminary net outflows for September 2025 were $2.0 billion. For the quarter-ended September 2025, net outflows were $7.9 billion, including $0.8 billion of manager-driven distributions.
Articles that caught my attention:
- Undervalued Dividend Growth Stock of the Week: A. O. Smith (AOS) by Jason Fieber at Daily Trade Alert
- Calling the bottom on Canadian telco stocks, on the Sunday Reads by Dale Roberts at Cut the Crap Investing
- Dividends Matter (A Lot) by Dividend Growth Investor
- My Top 10 High-Yield Dividend Stocks For October 2025: One Yields 11%-Plus by Frederik Mueller at Seeking Alpha
- 10 Consistent Dividend Stocks For Long-Term Income by Bob Ciura at Sure Dividend
- This Blue-Chip Giant’s Stock Is in the Gutter – Buy of the Decade? by Dan Kent at Stocktrades Canada
- Cummins: Watch This Dividend Aristocrat In The Making Now by Kody's Dividends at Seeking Alpha
- Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield by Jonathan Weber at Seeking Alpha
- Hormel Foods Corp. (HRL) Dividend Stock Analysis by D4L at Dividend Growth Stocks
- Low Debt Companies to Invest In by Mike at The Dividend Guy Blog
- If I Could Buy Just 3 High-Yield Dividend Stocks Right Now by Leo Nelissen at Seeking Alpha
Thanks for stopping by!
No comments:
Post a Comment